Glucagon-Like Peptide-1 Receptor Agonist Differentially Affects Brain Activation in Response to Visual Food Cues in Lean and Obese Individuals with Type 2 Diabetes Mellitus.
Diabetes Metab J · 2020
Last updated 2026-05-28In a study of 15 lean and 14 obese people with type 2 diabetes, brain scans showed that obese participants had stronger responses to high-calorie food images in areas like the hypothalamus and visual cortex compared to lean participants. After receiving a single dose of the GLP-1 drug lixisenatide, obese participants showed reduced brain activity in the fusiform gyrus and lateral ventricle when viewing high-calorie foods, while lean participants did not show the same change.
AI summary of the abstract below.
| Journal | Diabetes Metab J, 2020 |
|---|---|
| Citations | 24 |
| Relative citation ratio | 1.24 |
| NIH percentile | 58 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
BACKGROUND: To investigate the effects of a glucagon-like peptide-1 receptor agonist on functional brain activation in lean and obese individuals with type 2 diabetes mellitus (T2DM) in response to visual food cues.
METHODS: In a randomized, single-blinded, crossover study, 15 lean and 14 obese individuals with T2DM were administered lixisenatide or normal saline subcutaneously with a 1-week washout period. We evaluated brain activation in response to pictures of high-calorie food, low-calorie food, and nonfood using functional magnetic resonance imaging and measured appetite and caloric intake in participants who were given access to an buffet.
RESULTS: Obese individuals with T2DM showed significantly greater activation of the hypothalamus, pineal gland, parietal cortex (high-calorie food vs. low-calorie food, <0.05), orbitofrontal cortex (high-calorie food vs. nonfood, <0.05), and visual cortex (food vs. nonfood, <0.05) than lean individuals with T2DM. Lixisenatide injection significantly reduced the functional activation of the fusiform gyrus and lateral ventricle in obese individuals with T2DM compared with that in lean individuals with T2DM (nonfood vs. high-calorie food, <0.05). In addition, in individuals who decreased their caloric intake after lixisenatide injection, there were significant interaction effects between group and treatment in the posterior cingulate, medial frontal cortex (high-calorie food vs. low-calorie food, <0.05), hypothalamus, orbitofrontal cortex, and temporal lobe (food vs. nonfood, <0.05).
CONCLUSION: Brain responses to visual food cues were different in lean and obese individuals with T2DM. In addition, acute administration of lixisenatide differentially affected functional brain activation in these individuals, especially in those who decreased their caloric intake after lixisenatide injection.
Verbatim abstract via PubMed 31701698 ↗